| About the author: |
O. P. Bukach, I. O. Buzdugan |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of the study was to investigate the dynamics of the blood lipid spectrum under the influence of treatment depending on comorbid pathology and polymorphism of the gene T-786C endothelial nitric oxide synthase in patients with rheumatoid arthritis. 110 patients with rheumatoid arthritis and 20 practically healthy people were examined and treated. In the study, the concentration of high-density lipoprotein cholesterol decreased in patients with rheumatoid arthritis – by 22.3 %, rheumatoid arthritis, arterial hypertension – by 29.27 %, rheumatoid arthritis, arterial hypertension, abdominal obesity – by 33.61 %, rheumatoid arthritis, arterial hypertension, abdominal obesity, type 2 diabetes mellitus – by 44.55 %. The increase in total cholesterol, low-density lipoprotein cholesterol and triglycerides depending on the gene polymorphism is found in 87.5 %, 62.5 %, 100 % of patients with CC genotype, in 56.52 %, 47.83 %, 78.26 % of patients with TC genotype, 56.52 %, 37.93 % and in 75.86 % of patients with TT genotype. A comprehensive treatment of rheumatoid arthritis with comorbid pathology was proposed by adding telmisartan, rosuvastatin and L-arginine to the basic therapy. |
| Tags |
rheumatoid arthritis, comorbid pathology, dyslipidemia, polymorphism of the T-786C gene of endothelial nitric oxide synthase, rosuvastatin, telmisartan, L-arginine |
| Bibliography |
- Volkov VI. Effektivnost i bezopasnost statinov: vybor preparata. Zdorovya Ukrayiny. 2012;2(22):25–6. [In Russian]
- Holovach YIu, Vershynyna DV. Doklinicheskyi revmatoidnyi artrit. Ukrainskyi revmatolohichnyi zhurnal. 2016; 4 (66): 15–22. [In Russian]
- Zhdan VM, Lebid VH, Khaimenova HS, Ishcheikina Yu.O. Faktory ryzyku ishemichnoi khvoroby sertsia u khvorykh na revmatoidnyi artryt. Visnyk ukrainskoyi medychnoyi stomatolohichnoyi akademiyi. 2020; 20, 1 (69). 95–99. doi: 10.31718/2077-1096.20.1.95. [In Ukrainian]
- Stadnik SM. Rozuvastatin: novi mozhlivosti likuvannya aterosklerozu. Liky Ukrayiny. 2015;4:38–41. [In Ukrainian]
- Tkachenko VI, Kuharchuk KN. Lipidosnizhayuschaya terapiya – mera pervichnoy i vtorichnoy profilaktiki u patsientov s vyisokim serdechno-sosudistyim riskom (dislipidemiyey, arterialnoy gipertenziyey, sakharnym diabetom). Semeynaya meditsina. 2015;1:99–102. [In Russian]
- Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2021; 71(7): 1157–1162. doi: 10.1136/annrheumdis-2011-200493
- Сojocarua M, Сojocarub IM, Silosic I. Metabolic syndrome in rheumatoid arthritis. A Journal of Clinical Medicine. 2012; 2(7):148–52.
- Dessie G, Tadesse Y, Demelash B, Genet S. Assessment of Serum Lipid Profiles and High-sensitivity C-reactive Protein Among Patients Suffering from Rheumatoid Arthritis at Tikur Anbessa. Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study. Open Access Rheumatol. 2020; 12:223–232. PMID: 33061690. PMCID: PMC7520147. doi: 10.2147/OARRR.S264466
- Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis. Am J Manag Care. 2014 May; 20(7 Suppl):128–35.
- González-Gay MA, González-Juanatey C, Llorca J Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom? Ann Rheum Dis. 2012 Jun; 71(6):796–8. doi: 10.1136/annrheumdis-2011-201209.
- Ikdahl E, Hisdal J, Rollefstad S, Olsen IC, Kvien TK, Pedersen TR et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Research & Therapy. 2015 Oct; 17:279–285. https://doi.org/10.1186/s13075-015-0795-y.
- Ristic G, Subota V, Stanisavljevic D, Glisic B, Petronijevic M, Stefanovic D et al. Rheumatoid arthritis is an independent risk factor for increased insulin resistance and impaired beta-cell function: impact of disease activity. Arthritis Rheumatol. 2016 Sep; 68:1992–2002.
- Smolen JS, Lamdewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun; 76(6):960–977. doi: 10.1136/annrheumdis-2016-210715.
- Van de Stadt LA, van Sijl AM, van Schaardenburg D, Nurmohamed MT. Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis. Ann Rheum Dis. 2012 Nov; 71(11):1915–6. doi: 10.1136/annrheumdis-2012-201709.
- Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016 Jun; 8(3):86–101. doi: 10.1177/1759720X16643340.
|
| Publication of the article |
«World of Medicine and Biology» №2(80), 2022 year, 029-033 pages, index UDK 616.153.915:616.72-007.24]-036.1-07-08 |
| DOI |
10.26724/2079-8334-2022-2-80-29-33 |
